117 related articles for article (PubMed ID: 29976776)
41. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Illidge T; Bouabdallah R; Chen R; Gopal AK; Moskowitz CH; Ramchandren R; Shustov AR; Tilly H; Trippett TM; Gibb A; Grove LE; Advani R
Leuk Lymphoma; 2015 Mar; 56(3):703-10. PubMed ID: 24913507
[TBL] [Abstract][Full Text] [Related]
42. Time to Change Direction in the Treatment of Relapsed Hodgkin Lymphoma?
Crump M
J Clin Oncol; 2021 Jan; 39(2):97-99. PubMed ID: 33275485
[No Abstract] [Full Text] [Related]
43. Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.
Flerlage JE; Metzger ML; Wu J; Panetta JC
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1217-1223. PubMed ID: 27837256
[TBL] [Abstract][Full Text] [Related]
44. Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma.
Rubinstein PG; Moore PC; Rudek MA; Henry DH; Ramos JC; Ratner L; Reid E; Sharon E; Noy A;
AIDS; 2018 Mar; 32(5):605-611. PubMed ID: 29280762
[TBL] [Abstract][Full Text] [Related]
45. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience.
Rothe A; Sasse S; Goergen H; Eichenauer DA; Lohri A; Jäger U; Bangard C; Böll B; von Bergwelt Baildon M; Theurich S; Borchmann P; Engert A
Blood; 2012 Aug; 120(7):1470-2. PubMed ID: 22786877
[TBL] [Abstract][Full Text] [Related]
46. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study.
Hagenbeek A; Mooij H; Zijlstra J; Lugtenburg P; van Imhoff G; Nijland M; Tonino S; Hutchings M; Spiering M; Liu R; van Tinteren H; Kersten MJ
Haematologica; 2019 Apr; 104(4):e151-e153. PubMed ID: 30381303
[No Abstract] [Full Text] [Related]
47. Queen's gambit: response-adapted win in CAYA with cHL.
Tolu SS; Amengual JE
Blood; 2023 Apr; 141(17):2037-2038. PubMed ID: 37103949
[No Abstract] [Full Text] [Related]
48. Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma.
Dozzo M; Zaja F; Volpetti S; Sperotto A; Magli A; Fanin R
Am J Hematol; 2015 Apr; 90(4):E73. PubMed ID: 25546725
[No Abstract] [Full Text] [Related]
49. Brentuximab vedotin: its role in the treatment of anaplastic large cell and Hodgkin's lymphoma.
Haddley K
Drugs Today (Barc); 2012 Apr; 48(4):259-70. PubMed ID: 22536568
[TBL] [Abstract][Full Text] [Related]
50. Brentuximab vedotin consolidation post-autologous stem cell transplant in Hodgkin lymphoma patients at risk of residual disease: number needed to treat.
Gautam A; Zhu Y; Ma E; Lee SY; Zagadailov E; Teasell J; Richhariya A; Bonthapally V; Huebner D
Leuk Lymphoma; 2018 Jan; 59(1):69-76. PubMed ID: 28583027
[TBL] [Abstract][Full Text] [Related]
51. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
52. Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT.
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):7-8. PubMed ID: 27007003
[No Abstract] [Full Text] [Related]
53. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
Mediwake H; Morris K; Curley C; Butler J; Kennedy G
Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
[TBL] [Abstract][Full Text] [Related]
54. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
Gopal AK; Chen R; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Chi X; Sievers EL; Younes A
Blood; 2015 Feb; 125(8):1236-43. PubMed ID: 25533035
[TBL] [Abstract][Full Text] [Related]
55. Brentuximab vedotin as a salvage treatment for relapsed and refractory Hodgkin lymphoma patients in Taiwan.
Tien FM; Tsai CH; Liu JH; Lin CT
J Formos Med Assoc; 2019 Oct; 118(10):1466-1470. PubMed ID: 31337522
[TBL] [Abstract][Full Text] [Related]
56. [Effect of brentuximab vedotin combined with chlormethine hydrochloride on the treatment of 6 patients with relapsed and refractory Hodgkin lymphoma].
Cao Z; Wang Z; Sun J; Peng C; Feng S; Zhou X; Yang Q
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):575-7. PubMed ID: 26304081
[TBL] [Abstract][Full Text] [Related]
57. Pulmonary toxicity in paediatric patients with relapsed or refractory Hodgkin lymphoma receiving brentuximab vedotin.
Faulk KE; Sopfe JM; Campbell K; Liptzin DR; Liu AK; Franklin ARK; Cost CR
Br J Haematol; 2018 Oct; 183(2):251-256. PubMed ID: 30198571
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.
Moskowitz AJ; Schöder H; Gavane S; Thoren KL; Fleisher M; Yahalom J; McCall SJ; Cadzin BR; Fox SY; Gerecitano J; Grewal R; Hamlin PA; Horwitz SM; Kumar A; Matasar M; Ni A; Noy A; Palomba ML; Perales MA; Portlock CS; Sauter C; Straus D; Younes A; Zelenetz AD; Moskowitz CH
Blood; 2017 Nov; 130(20):2196-2203. PubMed ID: 28874350
[TBL] [Abstract][Full Text] [Related]
59. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.
Forero-Torres A; Holkova B; Goldschmidt J; Chen R; Olsen G; Boccia RV; Bordoni RE; Friedberg JW; Sharman JP; Palanca-Wessels MC; Wang Y; Yasenchak CA
Blood; 2015 Dec; 126(26):2798-804. PubMed ID: 26377597
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
